What are the take-home messages from 17-ICML?

During the 17th International Conference on Malignant Lymphomas (17-ICML), the Lymphoma Hub spoke with Martin Dreyling, Ludwig-Maximilians-Universität, Munich, DE. We asked, What are the take-home messages from 17-ICML?

Dreyling explains that Hodgkin's lymphoma was an important theme of the conference this year, he discusses:

• The SWOG 1826 trial of  finding nivolumab in combination with chemotherapy, which could be a new standard-of-care treatment for patients with relapsed/refractory Hodgkin’s lymphoma.
• The HD21 trial results concluding BrECADD has less treatment-related morbidities than eBEACOPP.
• Immunotherapy being considered as standard-of-care treatment for patients with aggressive lymphoma after from results of the ZUMA-7 trial; chimeric antigen receptor T-cell therapy is more successful as a second-line therapy than third-line.
• The EPCORE DLBCL-2 study summarizing epcoritimab + R-CHOP is feasible in patients as first-line treatment of DLBCL.

Drelying concludes that immunotherapy may challenge standard-of-care R-CHOP treatment in the first-line of treatment of DLBCL.